VJHemOnc is pleased to be the official media partner for the International Workshop on NHL (iwNHL) 2021, a high-level discussion forum for research leaders in the field of non-Hodgkin lymphoma (NHL).

Presentations and panel discussions with leading experts are now available to watch below.

iwNHL 2021

The International Workshop on NHL (iwNHL) 2021
06–08 May 2021 | Virtual Meeting

iwNHL 2021

The International Workshop on NHL (iwNHL) 2021
06–08 May 2021 | Virtual Meeting

VJHemOnc is pleased to be the official media partner for the International Workshop on NHL (iwNHL) 2021, a high-level discussion forum for research leaders in the field of non-Hodgkin lymphoma (NHL).

Presentations and panel discussions with leading experts are now available to watch below.

Session 1: T-Cell Lymphoma
Elaine  Jaffe
EBV-associated lymphoproliferations: pathobiology and spectrum
Elaine Jaffe National Cancer Institute, Bethesda, MD, United States
Olivier  Tournilhac
EBV-associated lymphoproliferations: clinical perspective
Olivier Tournilhac Clermont-Ferrand University Hospital, Clermont-Ferrand, France
Laurence  de Leval
Biology & management of BIA-ALCL: introduction to BIA-ALCL
Laurence de Leval Lausanne University Hospital, Lausanne, Switzerland
Miles  Prince
Biology & management of BIA-ALCL: experience from Australia
Miles Prince Peter MacCallum Cancer Centre, Melbourne, Australia
Neha  Mehta-Shah
Biology & management of BIA-ALCL: experience from the USA
Neha Mehta-Shah Washington University in St Louis, St Louis, MO, United States
Lorenzo  Falchi
Update and perspectives for epigenetic modifier therapy in PTCLs
Lorenzo Falchi Memorial Sloan Kettering Cancer Center, New York, NY, United States
Session 1 panel discussion
Session 2: Immunotherapy/Microenvironment
Patricia  Pérez Galán
Microenvironment in FL pathogenesis and therapy
Patricia Pérez Galán August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
Stephen Ansell
CBT in specific lymphoma subtypes
Stephen Ansell Mayo Clinic, Rochester, MN, AL, United States
Frederick Locke
CARs and the tumour microenvironment
Frederick Locke H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Francisco  Hernandez-Ilizaliturri
MIDS in combination
Francisco Hernandez-Ilizaliturri Roswell Park Cancer Institute, Buffalo, NY, United States
Session 2 panel discussion
Session 3: Mantle Cell Lymphoma
Elias  Campo
Mantle cell lymphoma
Elias Campo Hospital Clinic of the University of Barcelona, Barcelona, Spain
Session 3 panel discussion
Session 4: Novel Therapies Part I
Laurie  Sehn
ADCs: polatuzumab vedotin
Laurie Sehn BC Cancer Agency, Prince George, Canada
Graham Collins
ADCs: ADCT–301 camidanlumab tesirine
Graham Collins Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Stephen  Schuster
CD20/CD3 bispecific antibodies, how to choose?: mosunetuzumab
Stephen Schuster Perelman School of Medicine, Philadelphia, PA, United States
Franck Morschhauser
CD20/CD3 bispecific antibodies, how to choose?: CD20 TCB
Franck Morschhauser Lille University Hospital, Lille, France
Rajat  Bannerji
CD20/CD3 bispecific antibodies, how to choose?: REGN1979
Rajat Bannerji Rutgers Cancer institute of New Jersey, Newark, NJ, United States
Session 4 panel discussion
Session 5: Novel Therapies Part II
Thomas Witzig
Novel BTK inhibitors, how to choose?: acalabrutinib
Thomas Witzig Mayo Clinic Rochester, Rochester , MN, United States
Chan Yoon  Cheah
Novel BTK inhibitors, how to choose?: loxo-305
Chan Yoon Cheah Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia
Gilles  Salles
Novel BTK inhibitors, how to choose?: tirabrutinib
Gilles Salles Memorial Sloan Kettering Cancer Center, New York, NY, United States
Paolo Ghia
Novel BTK inhibitors, how to choose?: ibrutinib combinations
Paolo Ghia Università Vita-Salute San Raffaele, Milan, Italy
John  Kuruvilla
SINE inhibitors
John Kuruvilla Princess Margaret Cancer Centre, Toronto, Canada
Gilles  Salles
Tafasitamab (MOR208) in DLBCL
Gilles Salles Memorial Sloan Kettering Cancer Center, New York, NY, United States
Session 5 panel discussion
Session 6: T-cell Therapies for Lymphoma
Jeremy Abramson
Lisocabtagene maraleucel (liso-cel) in DLBCL
Jeremy Abramson Massachusetts General Hospital Cancer Center, Boston, MA, United States
Sattva  Neelapu
Axicabtagene ciloleucel (axi-cel) in DLBCL
Sattva Neelapu University of Texas MD Anderson Cancer Center, Houston, TX, United States
Stephen  Schuster
Tisagenlecleucel in DLBCL
Stephen Schuster Perelman School of Medicine, Philadelphia, PA, United States
Barbara  Savoldo
CD30-CAR T-cells
Barbara Savoldo University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
Max  Mamonkin
CD5 and/or 7 CAR T-cells
Max Mamonkin Baylor College of Medicine, Houston, TX, United States
Susan  Prockop
Third party EBV T-cells
Susan Prockop Memorial Sloan Kettering Cancer Center, New York, NY, United States
Session 6 panel discussion

Visit The Lymphoma channel for the latest updates from leading experts

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter